Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Tvardi Therapeutics (TVRD) EBIAT (2016 - 2025)

Tvardi Therapeutics' EBIAT history spans 13 years, with the latest figure at -$7.3 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 42.55% to -$7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$18.2 million, a 37.96% increase, with the full-year FY2025 number at -$18.2 million, up 38.09% from a year prior.
  • EBIAT hit -$7.3 million in Q4 2025 for Tvardi Therapeutics, down from -$5.5 million in the prior quarter.
  • Over the last five years, EBIAT for TVRD hit a ceiling of $4.2 million in Q2 2025 and a floor of -$33.4 million in Q4 2021.
  • Historically, EBIAT has averaged -$17.0 million across 5 years, with a median of -$17.9 million in 2022.
  • Biggest five-year swings in EBIAT: tumbled 2188.25% in 2022 and later skyrocketed 159.74% in 2025.
  • Tracing TVRD's EBIAT over 5 years: stood at -$33.4 million in 2021, then grew by 9.12% to -$30.3 million in 2022, then dropped by 6.59% to -$32.3 million in 2023, then surged by 60.7% to -$12.7 million in 2024, then skyrocketed by 42.55% to -$7.3 million in 2025.
  • Business Quant data shows EBIAT for TVRD at -$7.3 million in Q4 2025, -$5.5 million in Q3 2025, and $4.2 million in Q2 2025.